{"url_path":"/sec/btmd/8-k/2026-06-17/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K/A","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1819253/0001193125-26-274137-index.html","accession_number":"0001193125-26-274137","cik":"0001819253","ticker":"BTMD","issuer_name":"biote Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1819253/0001193125-26-274137-index.html","primary_entity_key":"0001819253","primary_entity_name":"biote Corp."},"word_count":457,"has_tables":true,"body_markdown":"8-K/A\n\n0001819253 0001819253 2026-06-12 2026-06-12\n\n \n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\n \n\n \n\nFORM 8-K/A\n\n \n\n \n\nCURRENT REPORT\n\nPURSUANT TO SECTION 13 OR 15(d)\n\nOF THE SECURITIES EXCHANGE ACT OF 1934\n\nDate of Report (Date of earliest event reported): June 12, 2026\n\n \n\n \n\nbiote Corp.\n\n(Exact name of registrant as specified in its charter)\n\n \n\n \n\n \n\nDelaware\n \n001-40128\n \n85-1791125\n\n(State or other jurisdiction\n\nof incorporation)\n\n \n\n(Commission\n\nFile Number)\n\n \n\n(I.R.S. Employer\n\nIdentification No.)\n\n \n\n1875 W. Walnut Hill Ln #100\n\nIrving, Texas 75038\n\n(Address of principal executive offices, including zip code)\n\n(844) 604-1246\n\n(Registrant’s telephone number, including area code)\n\n \n\n(Former name or former address, if changed since last report)\n\n \n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\n\n \n\nTrading\nSymbols\n\n \n\nName of each exchange\n\non which registered\n\nClass A common stock, par value $0.0001 per share\n \nBTMD\n \nThe Nasdaq Stock Market LLC\n\nCheck the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n☐\n\nWritten communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐\n\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐\n\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐\n\nPre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\nEmerging growth company ☒\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\n \n\n \n\nExplanatory Note\n\nThis Amendment No. 1 on Form 8-K/A is an amendment to the current report on Form 8-K of biote Corp. (the “Company”), filed on June 2, 2026 (the “Original Form 8-K”). As disclosed on the Original Form 8-K, the board of directors of the Company (the “Board”) appointed Robert Peterson, Chief Financial Officer and Chief Business Officer of BioTE Medical LLC (“BioTE”), as Interim Chief Executive Officer of BioTE, effective June 8, 2026. At the time of his appointment, the Board had not yet approved any compensatory agreements for Mr. Peterson in his new role.\n\nOn June 12, 2026, the Board approved and entered into an amended and restated employment agreement with Mr. Peterson. The Company is amending the Original Form 8-K to provide a description of the compensation arrangements and agreements for Mr. Peterson established in connection with his appointment as Interim Chief Executive Officer."}